2096 — Simcere Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$27.27bn
- HK$24.00bn
- CNY7.73bn
Brief: Simcere Pharmaceutical Says Clinical Trial Approval For SIM0686 Issued By NMPA
Brief: Simcere Pharmaceutical Says NDA Of Deunoxavir Marboxil Tablets Accepted By NMPA
Brief: Simcere Pharmaceutical Expects FY Adjusted Profit Attributable Near RMB1,003 Mln To RMB1,033 Mln
Brief: Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie
AbbVie secures option to license Simcere's blood cancer drug candidate (updated)
China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate
Brief: Simcere Pharmaceutical Says Clinical Trial Approval For SIM0505 Issued By NMPA
Brief: Simcere Pharmaceutical Gets Marketing Approval For Sanbexin Sublingual Tablets In China By NMPA
Brief: Simcere Pharmaceutical Says Cosela, Enlituo, And Sanbexin Included In New National Reimbursement Drug List
Brief: Simcere Pharmaceutical Says Breakthrough Therapy Designation Granted By U.S. FDA
Brief: Simcere Pharmaceutical Enters Cooperation Agreement With TargetRx
Brief: Simcere Pharmaceutical Says Clinical Trial Approval Issued By NMPA
Brief: Simcere Pharmaceutical Group Posts H1 Revenue Of RMB3,114 Mln
Brief: Simcere Pharmaceutical Sees Profit Attributable RMB427 Mln To RMB487 Mln For Six Months
Brief: Simcere Pharmaceutical Says New Drug Application Of Quviviq Accepted By NMPA
Brief: Simcere Pharmaceutical Says Regular Approval Of Xiannuoxin Approved By NMPA
Brief: Simcere Pharmaceutical Says Cetuximab Beta Injection Approved For Marketing In China By NMPA
Brief: Simcere Pharmaceutical Says Resolved To Repurchase Shares In Open Market
Brief: Simcere Pharmaceutical Says Phase 3 Clinical Study Of Daridorexant Hydrochloride Tablets In China Met Primary Endpoint